ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in ...

We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

ImmunityBio ( NASDAQ:IBRX ) Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from FY... CULVER CITY, Calif., March 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a ...

Reports Q4 revenue $7.55M, consensus $9.51M. “The first quarter of 2025 has been an inflection point for the Company with multiple milestones ...

ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...

SAN DIEGO — SAN DIEGO — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $59.2 million in its fourth quarter. The San Diego-based company said it had a loss of 9 cents per share. Losses, adjusted ...